ATLANTA, GA – Clearside Biomedical, Inc., a privately held company specializing in the research and development of ophthalmic pharmaceuticals, today announced the successful dosing of patients in a safety and tolerability clinical study using its proprietary ocular microinjection platform to deliver therapeutics to treat retinal disease.
Chapel Hill, NC – G1 Therapeutics, Inc. today announced that the company has partnered with Hatteras Venture Partners (HVP) to advance their drug discovery pipeline. G1 is progressing several novel pre- clinical small molecule inhibitors forward to provide protection of bone marrow and other organs against radiologic and chemotherapeutic insults.
STONY BROOK, NY – (MARKETWIRE via COMTEX) – Coferon Inc., a privately held, New York-based biotechnology company, today announced that it has closed on a $12 million Series B financing round led by a trio of new venture investors: Hatteras Venture Partners of Durham, N.C.; MedImmune Ventures of Gaithersburg, MD (the corporate venture arm of AstraZeneca Ltd); and Ascent Biomedical Ventures of New York, N.Y.
RALEIGH, NC – (BUSINESS WIRE) – Clinverse, Inc., the global cloud-based ecommerce platform provider for clinical buy legit tramadol online trials, announced today that it has closed a $3.8 million Series B round of funding led by Hatteras Venture Partners of Durham, NC. Vital Financial of Bethesda, MD, also participated in this funding round.
ATLANTA and DURHAM – (Business Wire) – Ophthalmic startup Clearside Biomedical, Inc. and Hatteras Venture Partners announce today that they have launched the company with a $4,000,000 Series A venture financing to fund the initial development of Clearside Biomedical’s ocular microinjection platform and initial clinical testing of Clearside Biomedical’s lead product for Macular Edema and Retinal Vein Occlusion.